In Situ Silver‐Based Electrochemical Oncolytic Bioreactor
In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20‐fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prod...
Gespeichert in:
| Veröffentlicht in: | Advanced materials (Weinheim) 2022-10, Vol.34 (40), p.e2109973-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 40 |
| container_start_page | e2109973 |
| container_title | Advanced materials (Weinheim) |
| container_volume | 34 |
| creator | Huang, Yong Zhong, Liping Li, Xiaotong Wu, Pan He, Jian Tang, Chao Tang, Zhiping Su, Jing Feng, Zhenbo Wang, Bing Ma, Yun Peng, Hongmei Bai, Zhihao Zhong, Yi Liang, Ying Lu, Wenxi Luo, Ruiyu Li, Jinghua Li, Haiping Deng, Zhiming Lan, Xianli Liu, Ziqun Zhang, Kun Zhao, Yongxiang |
| description | In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20‐fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prodrugs into in situ therapeutic silver nanoparticles with and above 95% transition rate is constructed to inhibit the growths of various tumors. In this SEOB‐enabled intratumoral nanosynthetic medicine, intratumoral H2O2 and rGO act as the reductant and the catalyst, respectively. Chelation of aptamers to the SEOB‐unlocked prodrugs increases the production of silver nanoparticles in tumor cells, especially in the presence of Vitamin C, which is broken down in tumor cells to supply massive amounts of H2O2. Consequently, apoptosis and pyroptosis are induced to cooperatively contribute to the considerably‐elevated anti‐tumor effects on subcutaneous HepG2 and A549 tumors and orthotopic implanted HepG2 tumors in livers of nude mice. The specific aptamer targeting and intratumoral silver nanoparticle production guarantee excellent biosafety since it fails to elicit tissue damages in monkeys, which greatly increases the clinical translation potential of the SEOB system.
A tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor has been established to unlock anti‐tumor Ag+ prodrugs for highly‐efficient subcutaneous and orthotopic tumor recession via activating reactive oxygen species production, wherein reduced graphene oxide featuring 20‐fold larger catalysis rate than graphene oxide allows intratumoral H2O2 as reductants to reduce Ag+ into silver nanoparticles especially after uniting with VitC‐mediated H2O2 production. |
| doi_str_mv | 10.1002/adma.202109973 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2721531080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2721531080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4133-cd576ec6f629c7a4135158a9526986e9ff655ab8827bc02719ad9dc9e96c4efa3</originalsourceid><addsrcrecordid>eNqFkEFPwjAUgBujEUSvHs0Sz8PXbu324gkQlQTDQT03peviyEax3TDc_An-Rn-JIyAevfQlzfe-l3yEXFLoUwB2o7JK9RkwCohJdES6lDMaxoD8mHQBIx6iiNMOOfN-AQAoQJySTsQRU06TLrmdLIPnom7ap1wb9_35NVTeZMG4NLp2Vr-ZqtCqDGZLbctNXehgWFhnlK6tOycnuSq9udjPHnm9H7-MHsPp7GEyGkxDHdMoCnXGE2G0yAVDnaj2j1OeKuRMYCoM5rngXM3TlCVzDSyhqDLMNBoUOja5inrkeuddOfveGF_LhW3csj0pWcIojyik0FL9HaWd9d6ZXK5cUSm3kRTktpXctpKHVu3C1V7bzCuTHfDfOC2AO-CjKM3mH50c3D0N_uQ_22B1gw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721531080</pqid></control><display><type>article</type><title>In Situ Silver‐Based Electrochemical Oncolytic Bioreactor</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Huang, Yong ; Zhong, Liping ; Li, Xiaotong ; Wu, Pan ; He, Jian ; Tang, Chao ; Tang, Zhiping ; Su, Jing ; Feng, Zhenbo ; Wang, Bing ; Ma, Yun ; Peng, Hongmei ; Bai, Zhihao ; Zhong, Yi ; Liang, Ying ; Lu, Wenxi ; Luo, Ruiyu ; Li, Jinghua ; Li, Haiping ; Deng, Zhiming ; Lan, Xianli ; Liu, Ziqun ; Zhang, Kun ; Zhao, Yongxiang</creator><creatorcontrib>Huang, Yong ; Zhong, Liping ; Li, Xiaotong ; Wu, Pan ; He, Jian ; Tang, Chao ; Tang, Zhiping ; Su, Jing ; Feng, Zhenbo ; Wang, Bing ; Ma, Yun ; Peng, Hongmei ; Bai, Zhihao ; Zhong, Yi ; Liang, Ying ; Lu, Wenxi ; Luo, Ruiyu ; Li, Jinghua ; Li, Haiping ; Deng, Zhiming ; Lan, Xianli ; Liu, Ziqun ; Zhang, Kun ; Zhao, Yongxiang</creatorcontrib><description>In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20‐fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prodrugs into in situ therapeutic silver nanoparticles with and above 95% transition rate is constructed to inhibit the growths of various tumors. In this SEOB‐enabled intratumoral nanosynthetic medicine, intratumoral H2O2 and rGO act as the reductant and the catalyst, respectively. Chelation of aptamers to the SEOB‐unlocked prodrugs increases the production of silver nanoparticles in tumor cells, especially in the presence of Vitamin C, which is broken down in tumor cells to supply massive amounts of H2O2. Consequently, apoptosis and pyroptosis are induced to cooperatively contribute to the considerably‐elevated anti‐tumor effects on subcutaneous HepG2 and A549 tumors and orthotopic implanted HepG2 tumors in livers of nude mice. The specific aptamer targeting and intratumoral silver nanoparticle production guarantee excellent biosafety since it fails to elicit tissue damages in monkeys, which greatly increases the clinical translation potential of the SEOB system.
A tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor has been established to unlock anti‐tumor Ag+ prodrugs for highly‐efficient subcutaneous and orthotopic tumor recession via activating reactive oxygen species production, wherein reduced graphene oxide featuring 20‐fold larger catalysis rate than graphene oxide allows intratumoral H2O2 as reductants to reduce Ag+ into silver nanoparticles especially after uniting with VitC‐mediated H2O2 production.</description><identifier>ISSN: 0935-9648</identifier><identifier>EISSN: 1521-4095</identifier><identifier>DOI: 10.1002/adma.202109973</identifier><identifier>PMID: 35998517</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>5,5′,6,6′‐tetrachloro‐1,1,3,3′‐tetraethylbenzimidazolyl carbocyanine iodide ; Animals ; Apoptosis ; aptamer targeting ; Ascorbic Acid ; Bioreactors ; Catalysis ; Chelation ; Drugs ; Electrochemical Techniques ; Graphene ; Graphite ; Hydrogen peroxide ; intratumoral silver‐based nanosynthetic prodrugs ; Materials science ; Metal Nanoparticles ; Mice ; Mice, Nude ; Nanoparticles ; primate biosafety ; Prodrugs ; Reducing Agents ; Silver ; silver‐based electrochemical oncolytic bioreactors ; Tumors</subject><ispartof>Advanced materials (Weinheim), 2022-10, Vol.34 (40), p.e2109973-n/a</ispartof><rights>2022 The Authors. Advanced Materials published by Wiley‐VCH GmbH</rights><rights>2022 The Authors. Advanced Materials published by Wiley-VCH GmbH.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4133-cd576ec6f629c7a4135158a9526986e9ff655ab8827bc02719ad9dc9e96c4efa3</citedby><cites>FETCH-LOGICAL-c4133-cd576ec6f629c7a4135158a9526986e9ff655ab8827bc02719ad9dc9e96c4efa3</cites><orcidid>0000-0003-2214-5887</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadma.202109973$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadma.202109973$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35998517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yong</creatorcontrib><creatorcontrib>Zhong, Liping</creatorcontrib><creatorcontrib>Li, Xiaotong</creatorcontrib><creatorcontrib>Wu, Pan</creatorcontrib><creatorcontrib>He, Jian</creatorcontrib><creatorcontrib>Tang, Chao</creatorcontrib><creatorcontrib>Tang, Zhiping</creatorcontrib><creatorcontrib>Su, Jing</creatorcontrib><creatorcontrib>Feng, Zhenbo</creatorcontrib><creatorcontrib>Wang, Bing</creatorcontrib><creatorcontrib>Ma, Yun</creatorcontrib><creatorcontrib>Peng, Hongmei</creatorcontrib><creatorcontrib>Bai, Zhihao</creatorcontrib><creatorcontrib>Zhong, Yi</creatorcontrib><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Lu, Wenxi</creatorcontrib><creatorcontrib>Luo, Ruiyu</creatorcontrib><creatorcontrib>Li, Jinghua</creatorcontrib><creatorcontrib>Li, Haiping</creatorcontrib><creatorcontrib>Deng, Zhiming</creatorcontrib><creatorcontrib>Lan, Xianli</creatorcontrib><creatorcontrib>Liu, Ziqun</creatorcontrib><creatorcontrib>Zhang, Kun</creatorcontrib><creatorcontrib>Zhao, Yongxiang</creatorcontrib><title>In Situ Silver‐Based Electrochemical Oncolytic Bioreactor</title><title>Advanced materials (Weinheim)</title><addtitle>Adv Mater</addtitle><description>In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20‐fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prodrugs into in situ therapeutic silver nanoparticles with and above 95% transition rate is constructed to inhibit the growths of various tumors. In this SEOB‐enabled intratumoral nanosynthetic medicine, intratumoral H2O2 and rGO act as the reductant and the catalyst, respectively. Chelation of aptamers to the SEOB‐unlocked prodrugs increases the production of silver nanoparticles in tumor cells, especially in the presence of Vitamin C, which is broken down in tumor cells to supply massive amounts of H2O2. Consequently, apoptosis and pyroptosis are induced to cooperatively contribute to the considerably‐elevated anti‐tumor effects on subcutaneous HepG2 and A549 tumors and orthotopic implanted HepG2 tumors in livers of nude mice. The specific aptamer targeting and intratumoral silver nanoparticle production guarantee excellent biosafety since it fails to elicit tissue damages in monkeys, which greatly increases the clinical translation potential of the SEOB system.
A tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor has been established to unlock anti‐tumor Ag+ prodrugs for highly‐efficient subcutaneous and orthotopic tumor recession via activating reactive oxygen species production, wherein reduced graphene oxide featuring 20‐fold larger catalysis rate than graphene oxide allows intratumoral H2O2 as reductants to reduce Ag+ into silver nanoparticles especially after uniting with VitC‐mediated H2O2 production.</description><subject>5,5′,6,6′‐tetrachloro‐1,1,3,3′‐tetraethylbenzimidazolyl carbocyanine iodide</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>aptamer targeting</subject><subject>Ascorbic Acid</subject><subject>Bioreactors</subject><subject>Catalysis</subject><subject>Chelation</subject><subject>Drugs</subject><subject>Electrochemical Techniques</subject><subject>Graphene</subject><subject>Graphite</subject><subject>Hydrogen peroxide</subject><subject>intratumoral silver‐based nanosynthetic prodrugs</subject><subject>Materials science</subject><subject>Metal Nanoparticles</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Nanoparticles</subject><subject>primate biosafety</subject><subject>Prodrugs</subject><subject>Reducing Agents</subject><subject>Silver</subject><subject>silver‐based electrochemical oncolytic bioreactors</subject><subject>Tumors</subject><issn>0935-9648</issn><issn>1521-4095</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNqFkEFPwjAUgBujEUSvHs0Sz8PXbu324gkQlQTDQT03peviyEax3TDc_An-Rn-JIyAevfQlzfe-l3yEXFLoUwB2o7JK9RkwCohJdES6lDMaxoD8mHQBIx6iiNMOOfN-AQAoQJySTsQRU06TLrmdLIPnom7ap1wb9_35NVTeZMG4NLp2Vr-ZqtCqDGZLbctNXehgWFhnlK6tOycnuSq9udjPHnm9H7-MHsPp7GEyGkxDHdMoCnXGE2G0yAVDnaj2j1OeKuRMYCoM5rngXM3TlCVzDSyhqDLMNBoUOja5inrkeuddOfveGF_LhW3csj0pWcIojyik0FL9HaWd9d6ZXK5cUSm3kRTktpXctpKHVu3C1V7bzCuTHfDfOC2AO-CjKM3mH50c3D0N_uQ_22B1gw</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Huang, Yong</creator><creator>Zhong, Liping</creator><creator>Li, Xiaotong</creator><creator>Wu, Pan</creator><creator>He, Jian</creator><creator>Tang, Chao</creator><creator>Tang, Zhiping</creator><creator>Su, Jing</creator><creator>Feng, Zhenbo</creator><creator>Wang, Bing</creator><creator>Ma, Yun</creator><creator>Peng, Hongmei</creator><creator>Bai, Zhihao</creator><creator>Zhong, Yi</creator><creator>Liang, Ying</creator><creator>Lu, Wenxi</creator><creator>Luo, Ruiyu</creator><creator>Li, Jinghua</creator><creator>Li, Haiping</creator><creator>Deng, Zhiming</creator><creator>Lan, Xianli</creator><creator>Liu, Ziqun</creator><creator>Zhang, Kun</creator><creator>Zhao, Yongxiang</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><orcidid>https://orcid.org/0000-0003-2214-5887</orcidid></search><sort><creationdate>20221001</creationdate><title>In Situ Silver‐Based Electrochemical Oncolytic Bioreactor</title><author>Huang, Yong ; Zhong, Liping ; Li, Xiaotong ; Wu, Pan ; He, Jian ; Tang, Chao ; Tang, Zhiping ; Su, Jing ; Feng, Zhenbo ; Wang, Bing ; Ma, Yun ; Peng, Hongmei ; Bai, Zhihao ; Zhong, Yi ; Liang, Ying ; Lu, Wenxi ; Luo, Ruiyu ; Li, Jinghua ; Li, Haiping ; Deng, Zhiming ; Lan, Xianli ; Liu, Ziqun ; Zhang, Kun ; Zhao, Yongxiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4133-cd576ec6f629c7a4135158a9526986e9ff655ab8827bc02719ad9dc9e96c4efa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>5,5′,6,6′‐tetrachloro‐1,1,3,3′‐tetraethylbenzimidazolyl carbocyanine iodide</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>aptamer targeting</topic><topic>Ascorbic Acid</topic><topic>Bioreactors</topic><topic>Catalysis</topic><topic>Chelation</topic><topic>Drugs</topic><topic>Electrochemical Techniques</topic><topic>Graphene</topic><topic>Graphite</topic><topic>Hydrogen peroxide</topic><topic>intratumoral silver‐based nanosynthetic prodrugs</topic><topic>Materials science</topic><topic>Metal Nanoparticles</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Nanoparticles</topic><topic>primate biosafety</topic><topic>Prodrugs</topic><topic>Reducing Agents</topic><topic>Silver</topic><topic>silver‐based electrochemical oncolytic bioreactors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yong</creatorcontrib><creatorcontrib>Zhong, Liping</creatorcontrib><creatorcontrib>Li, Xiaotong</creatorcontrib><creatorcontrib>Wu, Pan</creatorcontrib><creatorcontrib>He, Jian</creatorcontrib><creatorcontrib>Tang, Chao</creatorcontrib><creatorcontrib>Tang, Zhiping</creatorcontrib><creatorcontrib>Su, Jing</creatorcontrib><creatorcontrib>Feng, Zhenbo</creatorcontrib><creatorcontrib>Wang, Bing</creatorcontrib><creatorcontrib>Ma, Yun</creatorcontrib><creatorcontrib>Peng, Hongmei</creatorcontrib><creatorcontrib>Bai, Zhihao</creatorcontrib><creatorcontrib>Zhong, Yi</creatorcontrib><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Lu, Wenxi</creatorcontrib><creatorcontrib>Luo, Ruiyu</creatorcontrib><creatorcontrib>Li, Jinghua</creatorcontrib><creatorcontrib>Li, Haiping</creatorcontrib><creatorcontrib>Deng, Zhiming</creatorcontrib><creatorcontrib>Lan, Xianli</creatorcontrib><creatorcontrib>Liu, Ziqun</creatorcontrib><creatorcontrib>Zhang, Kun</creatorcontrib><creatorcontrib>Zhao, Yongxiang</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><jtitle>Advanced materials (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yong</au><au>Zhong, Liping</au><au>Li, Xiaotong</au><au>Wu, Pan</au><au>He, Jian</au><au>Tang, Chao</au><au>Tang, Zhiping</au><au>Su, Jing</au><au>Feng, Zhenbo</au><au>Wang, Bing</au><au>Ma, Yun</au><au>Peng, Hongmei</au><au>Bai, Zhihao</au><au>Zhong, Yi</au><au>Liang, Ying</au><au>Lu, Wenxi</au><au>Luo, Ruiyu</au><au>Li, Jinghua</au><au>Li, Haiping</au><au>Deng, Zhiming</au><au>Lan, Xianli</au><au>Liu, Ziqun</au><au>Zhang, Kun</au><au>Zhao, Yongxiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Situ Silver‐Based Electrochemical Oncolytic Bioreactor</atitle><jtitle>Advanced materials (Weinheim)</jtitle><addtitle>Adv Mater</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>34</volume><issue>40</issue><spage>e2109973</spage><epage>n/a</epage><pages>e2109973-n/a</pages><issn>0935-9648</issn><eissn>1521-4095</eissn><abstract>In this study, it is shown for the first time that a reduced graphene oxide (rGO) carrier has a 20‐fold higher catalysis rate than graphene oxide in Ag+ reduction. Based on this, a tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor (SEOB) which switched Ag+ prodrugs into in situ therapeutic silver nanoparticles with and above 95% transition rate is constructed to inhibit the growths of various tumors. In this SEOB‐enabled intratumoral nanosynthetic medicine, intratumoral H2O2 and rGO act as the reductant and the catalyst, respectively. Chelation of aptamers to the SEOB‐unlocked prodrugs increases the production of silver nanoparticles in tumor cells, especially in the presence of Vitamin C, which is broken down in tumor cells to supply massive amounts of H2O2. Consequently, apoptosis and pyroptosis are induced to cooperatively contribute to the considerably‐elevated anti‐tumor effects on subcutaneous HepG2 and A549 tumors and orthotopic implanted HepG2 tumors in livers of nude mice. The specific aptamer targeting and intratumoral silver nanoparticle production guarantee excellent biosafety since it fails to elicit tissue damages in monkeys, which greatly increases the clinical translation potential of the SEOB system.
A tumor microenvironment‐enabled in situ silver‐based electrochemical oncolytic bioreactor has been established to unlock anti‐tumor Ag+ prodrugs for highly‐efficient subcutaneous and orthotopic tumor recession via activating reactive oxygen species production, wherein reduced graphene oxide featuring 20‐fold larger catalysis rate than graphene oxide allows intratumoral H2O2 as reductants to reduce Ag+ into silver nanoparticles especially after uniting with VitC‐mediated H2O2 production.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35998517</pmid><doi>10.1002/adma.202109973</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2214-5887</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0935-9648 |
| ispartof | Advanced materials (Weinheim), 2022-10, Vol.34 (40), p.e2109973-n/a |
| issn | 0935-9648 1521-4095 |
| language | eng |
| recordid | cdi_proquest_journals_2721531080 |
| source | MEDLINE; Wiley Journals |
| subjects | 5,5′,6,6′‐tetrachloro‐1,1,3,3′‐tetraethylbenzimidazolyl carbocyanine iodide Animals Apoptosis aptamer targeting Ascorbic Acid Bioreactors Catalysis Chelation Drugs Electrochemical Techniques Graphene Graphite Hydrogen peroxide intratumoral silver‐based nanosynthetic prodrugs Materials science Metal Nanoparticles Mice Mice, Nude Nanoparticles primate biosafety Prodrugs Reducing Agents Silver silver‐based electrochemical oncolytic bioreactors Tumors |
| title | In Situ Silver‐Based Electrochemical Oncolytic Bioreactor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A51%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Situ%20Silver%E2%80%90Based%20Electrochemical%20Oncolytic%20Bioreactor&rft.jtitle=Advanced%20materials%20(Weinheim)&rft.au=Huang,%20Yong&rft.date=2022-10-01&rft.volume=34&rft.issue=40&rft.spage=e2109973&rft.epage=n/a&rft.pages=e2109973-n/a&rft.issn=0935-9648&rft.eissn=1521-4095&rft_id=info:doi/10.1002/adma.202109973&rft_dat=%3Cproquest_cross%3E2721531080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721531080&rft_id=info:pmid/35998517&rfr_iscdi=true |